share_log

HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target

HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target

HC Wainwright & Co.重申買入 Acumen Pharmicals,維持15美元的目標價格
Benzinga ·  2023/08/09 06:30

HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 price target.

HC Wainwright & Co. 分析師安德魯·費恩重申Acumen Pharmicals(納斯達克股票代碼:ABOS)的買入,並維持15美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論